Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Explore this paper's citation graph
Summary
An 84-gene GS associated with clinical response for MAGE-A3 immunotherapeutic was identified in metastatic melanoma and confirmed in resected NSCLC, suggesting that their pretreatment expression influences the tumor's immune microenvironment and the patient's clinical response.
- Type
- article
- Published
- 2013-07-01
- Cited by
- 364
- References
- 39
- Access
- Open access
- OpenAlex
- https://openalex.org/W23715562
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:23625114
Keywords
Humanities, Art
References
- Human tumor-specific T lymphocytes: does function matter more than number?
- Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1
- BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes.
- T cell defined tumor antigens.
- A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
- Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
- Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
- REporting recommendations for tumour MARKer prognostic studies (REMARK)
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer.
- Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.
- Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma
- Structure, chromosomal localization, and expression of 12 genes of the MAGE family
- REporting recommendations for tumor MARKer prognostic studies (REMARK)
- A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
- Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
- Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
- Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in a Randomized Trial of Chemotherapy for Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer
Cited by
- Cancer immunotherapy: accomplishments to date and future promise.
- Cancer–Testis Antigen Expression in Digestive Tract Carcinomas: Frequent Expression in Esophageal Squamous Cell Carcinoma and Its Precursor Lesions
- Cancer vaccines: limited success but the research should remain viable
- Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy
- From Famine to Feast: Developing Early Phase Combination Immunotherapy Trials Wisely
- New Approaches in Immunotherapy for the Treatment of Lung Cancer.
- Prognostic and predictive markers for the new immunotherapies.
- Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy.
- Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.
- The path forward.
- The role of active vaccination in cancer immunotherapy: lessons from clinical trials.
- Control of CD8 T-cell Infiltration into Tumors by Vasculature and Microenvironment
- THERMAL ABLATION ALTERS THE TUMOR MICROENVIRONMENT ACTIVATING A ROBUST IMMUNE RESPONSE.
- Current methods of epitope identification for cancer vaccine design.
- Personalized approaches to active immunotherapy in cancer.
- Immunotherapies for bladder cancer: a new hope
- Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma
- The immune-related role of BRAF in melanoma
- 非小细胞肺癌免疫治疗进展
- Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression
Related papers
No related papers recorded.